Position in ABVX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$54,636,600
New position
Shares Held
410,000
first reported quarter
Ownership
0.470%
of shares outstanding
% of Portfolio
1.42%
of 13F equity value
Holder Rank
#36
of 301 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 80%
Shared 0%
None 20%
Derivatives in ABVX
reported options exposure · as of Jun 30, 2026CallValue
$0
CallShares
0
PutValue
$21,321,600
PutShares
160,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC holds $293,644,011 across 5 Biotechnology names. ABVX ranks #4 (18.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
830,247 | $67,673,432 | |
| 2 | ORKA |
Oruka Therapeutics, Inc.
|
658,301 | $62,650,506 | |
| 3 | IONS |
Ionis Pharmaceuticals Inc
|
787,263 | $62,422,083 | |
| 4 | ABVX |
Abivax S.A.
This page
|
410,000 | $54,636,600 | |
| 5 | BBIO |
BridgeBio Pharma, Inc.
|
621,125 | $46,261,390 |
All Filings in ABVX
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $21,321,600 | 160,000 | Put | Sole | 2026-08-14 | |
| 2026-06-30 | $54,636,600 | 410,000 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||